Colorectal CancerNCT05632744
Evaluation of CG-100 Intraluminal Bypass Device
A study testing CG-100 Intraluminal Bypass Device in people with Colorectal Cancer, run by Colospan Ltd. at 1 site in Israel.
Trial summary
Evaluation of CG-100 Intraluminal Bypass device Read more about this study
- Who is it for?
- Ages 22 to 75 years
- Conditions the study is for
- Colorectal Cancer
- What is being tested?
- CG-100 Intraluminal Bypass Device
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 7 participants
- Where
- 1 siteIsrael
- Study dates
- 15 Mar 2023to 15 Apr 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 22 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Willing to comply with protocol-specified follow-up evaluations
- 22-75 (inclusive) years of age at screening
- Diagnosed with colorectal cancer
- Has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country.
About this study
Evaluation of CG-100 Intraluminal Bypass device
- Conditions
- Colorectal Cancer
- Being tested
- CG-100 Intraluminal Bypass Device
- Medical subject headings
- Colorectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CG-100 Intraluminal Bypass DeviceDevice
Subjects will be treated with the CG-100 Intraluminal Bypass Device
| Study group | Role | What they receive |
|---|---|---|
| CG-100 Intraluminal Bypass Device | Experimental | Subjects will be treated with CG-100 Intraluminal Bypass Device Receives: Device: CG-100 Intraluminal Bypass Device |
What is being measured
The primary outcome is the main question the study is designed to answer.
Safety of the CG-100 Intraluminal Bypass Device
Assessment of Serious Adverse Events
Measured: 10 days
Secondary outcomes (1)
Safety of the CG-100 Intraluminal Bypass Device
Assessment of Serious Adverse Events
Measured: 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Dec 2022
- Study start15 Mar 2023
- Primary completion15 Apr 2024
- Study completion15 Apr 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Colorectal CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 7 participants (actual)
Sponsor and investigators
- Lead sponsor
- Colospan Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05632744
- Sponsor's protocol ID
- CLD-113
- Status last verified
- Jul 2026
- First submitted
- 8 Nov 2022
- Last updated
- 2 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of CG-100 Intraluminal Bypass Device
- ClinicalTrials.gov ID
- NCT05632744
- Acronym / sponsor ID
- CLD-113
- Conditions
- Colorectal Cancer
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 7 participants (actual)
- Lead sponsor
- Colospan Ltd.Industry (pharma, biotech, devices)
- Study start
- 15 Mar 2023 (actual)
- Primary completion
- 15 Apr 2024 (actual)
- Study completion
- 15 Apr 2024 (actual)
- First posted
- 1 Dec 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Evaluation of CG-100 Intraluminal Bypass device
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| CG-100 Intraluminal Bypass Device | Experimental | Device: CG-100 Intraluminal Bypass DeviceSubjects will be treated with CG-100 Intraluminal Bypass Device |
Who may qualify
- Ages
- 22 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Willing to comply with protocol-specified follow-up evaluations
- 22-75 (inclusive) years of age at screening
- Diagnosed with colorectal cancer
- Has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CG-100 Intraluminal Bypass DeviceSubjects will be treated with the CG-100 Intraluminal Bypass Device | Device | CG-100 Intraluminal Bypass Device |
Primary outcome
Safety of the CG-100 Intraluminal Bypass Device
Time frame: 10 days
Assessment of Serious Adverse Events
1 secondary outcome
Safety of the CG-100 Intraluminal Bypass Device
Time frame: 4 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Colorectal Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingObservational study
Pre- and On-treatment Multi-omics Profiling of Locally Advanced Rectal Cancer
Rectal Neoplasms
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 2
Tislelizumab in People With Colorectal Cancer
Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing CG-100 Intraluminal Bypass Device in people with Colorectal Cancer, run by Colospan Ltd. at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Safety of the CG-100 Intraluminal Bypass Device (time frame: 10 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jul 2026.